CL2018000883A1 - Moduladores del receptor x farnesoide - Google Patents

Moduladores del receptor x farnesoide

Info

Publication number
CL2018000883A1
CL2018000883A1 CL2018000883A CL2018000883A CL2018000883A1 CL 2018000883 A1 CL2018000883 A1 CL 2018000883A1 CL 2018000883 A CL2018000883 A CL 2018000883A CL 2018000883 A CL2018000883 A CL 2018000883A CL 2018000883 A1 CL2018000883 A1 CL 2018000883A1
Authority
CL
Chile
Prior art keywords
farnesoid
modulators
receiver
receiver modulators
cyclopentanoperhydrophenantrene
Prior art date
Application number
CL2018000883A
Other languages
English (en)
Inventor
Roberto Pellicciari
Antimo Gioiello
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of CL2018000883A1 publication Critical patent/CL2018000883A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Abstract

<p>COMPUESTO DERIVADOS DE CICLOPENTANOPERHIDROFENANTRENO, MODULADORES DEL RECEPTOR FARNESOIDE; COMPOSICION FARAMCEUTICA QUE LOS COMPRENDE; METODO PARA SU USO EN ENFERMEDADES GASTROINTESTINALES, CARDIOVASCULARES, ENTRE OTRAS.</p>
CL2018000883A 2015-10-07 2018-04-05 Moduladores del receptor x farnesoide CL2018000883A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562238246P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
CL2018000883A1 true CL2018000883A1 (es) 2018-06-29

Family

ID=58488545

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000883A CL2018000883A1 (es) 2015-10-07 2018-04-05 Moduladores del receptor x farnesoide

Country Status (27)

Country Link
US (2) US11034717B2 (es)
EP (2) EP3981779A1 (es)
JP (2) JP7021080B2 (es)
KR (1) KR20180061351A (es)
CN (1) CN108348530B (es)
AR (1) AR106293A1 (es)
AU (1) AU2016335765B2 (es)
BR (1) BR112018006892B1 (es)
CA (1) CA3000881C (es)
CL (1) CL2018000883A1 (es)
CO (1) CO2018003728A2 (es)
CR (1) CR20180201A (es)
DK (1) DK3359160T3 (es)
EA (1) EA038665B1 (es)
EC (1) ECSP18030284A (es)
ES (1) ES2898705T3 (es)
HK (1) HK1253558A1 (es)
IL (1) IL258359B2 (es)
MA (2) MA42339A1 (es)
MX (1) MX2018004186A (es)
PH (1) PH12018500777A1 (es)
SV (1) SV2018005662A (es)
TN (1) TN2018000106A1 (es)
TW (1) TW201718621A (es)
UA (1) UA123948C2 (es)
WO (1) WO2017062763A1 (es)
ZA (1) ZA201802901B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017118569A (ru) 2014-11-06 2018-12-06 Энанта Фармасьютикалс, Инк. Аналоги желчных кислот как агонисты fxr/tgr5 и способы их применения
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
HUE054960T2 (hu) 2015-03-31 2021-10-28 Enanta Pharm Inc Epesav származékok, mint az FXR/TGR5 agonista és annak felhasználási módszerei
BR112018006892B1 (pt) * 2015-10-07 2023-04-11 Intercept Pharmaceuticals, Inc Composto, composição farmacêutica do mesmo e seus usos como moduladores do receptor farnesoide x
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX2019006165A (es) 2016-11-29 2019-10-14 Enanta Pharm Inc Proceso para la preparacion de derivados del acido biliar de las sulfonilureas.
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
MX2019011844A (es) 2017-04-07 2021-11-30 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato.
JP7224307B2 (ja) 2017-06-23 2023-02-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法及び中間体
AU2018307611A1 (en) 2017-07-24 2020-02-06 Intercept Pharmaceuticals, Inc. Isotopically labeled bile acid derivatives
CN109929005B (zh) * 2017-12-19 2020-10-30 西安奥立泰医药科技有限公司 用于代谢性疾病治疗的化合物及其制备方法和应用
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
BR112021024109A2 (pt) 2019-05-30 2022-03-22 Intercept Pharmaceuticals Inc Composições farmacêuticas compreendendo um agonista fxr e um fibrato para uso no tratamento de doença hepática colestática
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2599481A (en) * 1948-09-28 1952-06-03 Ciba Pharm Prod Inc Reduction of steroid epoxides
DE3366932D1 (en) * 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1223313B (it) 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
DE10113257C1 (de) 2001-03-19 2002-11-14 Inst Mikrotechnik Mainz Gmbh Elektrophoresevorrichtung und ihre Verwendung
US20070197484A1 (en) 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
SI2040713T1 (sl) * 2006-06-27 2014-11-28 Intercept Pharmaceuticals, Inc. Derivati žolčne kisline kot FXR ligandi za preprečevanje ali zdravljenje bolezni ali stanj, posredovanih s FXR
CA2744189C (en) * 2008-11-19 2016-10-11 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
EP3336097B1 (en) 2012-06-19 2020-08-19 Intercept Pharmaceuticals, Inc. Preparation of the non-crystalline form of obeticholic acid
BR112015012312A2 (pt) 2012-11-28 2017-07-11 Intercept Pharmaceuticals Inc método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
ES2671427T3 (es) 2013-05-14 2018-06-06 Intercept Pharmaceuticals, Inc. Derivados 11-hidroxil-6-sustituidos de ácidos biliares y conjugados de aminoácidos de los mismos como moduladores de receptores farnesoides X
US9351083B2 (en) 2013-10-17 2016-05-24 Turtle Beach Corporation Transparent parametric emitter
RU2017121457A (ru) * 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US11578097B2 (en) * 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10405551B2 (en) 2015-10-07 2019-09-10 Stoller Enterprises, Inc. Managing ethylene in plants using a synergistic agricultural formula comprising diacyl or diaryl urea and at least one metal complex
BR112018006892B1 (pt) 2015-10-07 2023-04-11 Intercept Pharmaceuticals, Inc Composto, composição farmacêutica do mesmo e seus usos como moduladores do receptor farnesoide x
SI3426348T1 (sl) * 2016-03-11 2021-11-30 Intercept Pharmaceuticals, Inc. Derivat 3-dezoksi in njegovi farmacevtski sestavki
JP7224307B2 (ja) * 2017-06-23 2023-02-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法及び中間体

Also Published As

Publication number Publication date
DK3359160T3 (da) 2021-11-22
HK1253558A1 (zh) 2019-06-21
IL258359B1 (en) 2023-07-01
JP7021080B2 (ja) 2022-02-16
UA123948C2 (uk) 2021-06-30
EP3359160A4 (en) 2019-06-05
TN2018000106A1 (en) 2019-10-04
JP2018530559A (ja) 2018-10-18
KR20180061351A (ko) 2018-06-07
ZA201802901B (en) 2019-07-31
CO2018003728A2 (es) 2018-07-31
JP2019210297A (ja) 2019-12-12
ES2898705T3 (es) 2022-03-08
US11034717B2 (en) 2021-06-15
AR106293A1 (es) 2018-01-03
EA038665B1 (ru) 2021-09-30
EP3359160B1 (en) 2021-08-25
EA201890899A1 (ru) 2018-09-28
EP3359160A1 (en) 2018-08-15
CN108348530B (zh) 2023-09-29
MX2018004186A (es) 2018-05-17
AU2016335765A1 (en) 2018-04-19
US20210269475A1 (en) 2021-09-02
SV2018005662A (es) 2018-12-14
BR112018006892A2 (pt) 2018-10-16
IL258359B2 (en) 2023-11-01
WO2017062763A1 (en) 2017-04-13
BR112018006892B1 (pt) 2023-04-11
TW201718621A (zh) 2017-06-01
IL258359A (en) 2018-06-28
ECSP18030284A (es) 2018-05-31
AU2016335765B2 (en) 2022-01-06
PH12018500777A1 (en) 2018-10-29
CN108348530A (zh) 2018-07-31
CA3000881C (en) 2024-03-19
CR20180201A (es) 2018-08-24
EP3981779A1 (en) 2022-04-13
US20170101434A1 (en) 2017-04-13
MA42339A1 (fr) 2019-01-31
CA3000881A1 (en) 2017-04-13
MA45761A (fr) 2021-04-21

Similar Documents

Publication Publication Date Title
CL2018000883A1 (es) Moduladores del receptor x farnesoide
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
DK3490565T3 (da) Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
CL2018000819A1 (es) Anticuerpos biespecíficos anti-cd20 humano/receptor de transferrina humano y métodos para su uso
DOP2015000058A (es) Derivados tricíclicos de quinolinas y de quinoxalinas
CO7151531A2 (es) Anticuerpos e inmunoconjugados contra ly6e y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
DK3377483T3 (da) N-substituerede indolderivater som pge2-receptormodulatorer
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CL2016002008A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2018003045A1 (es) Semaglutida en afecciones cardiovasculares.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos